期刊文献+

昼夜节律紊乱与阿尔兹海默病的关系研究进展

Research progress on the relationship between circadian rhythm disturbance and Alzheimer’s disease
下载PDF
导出
摘要 阿尔兹海默病(Alzheimer’s disease,AD)是一种常见的神经退行性疾病,其病理特征包括β淀粉样蛋白(β-amyloid,Aβ)沉积、神经元死亡和认知能力下降等。近年来,越来越多的研究表明,生物钟或昼夜节律紊乱与AD的发生和发展密切相关。25-40%的AD患者同时伴有不同程度的昼夜节律紊乱症状,出现夜间睡眠片段化、白天小睡增加等症状。研究结果表明,AD与节律紊乱可通过Aβ的生成和清除,神经元的损伤和死亡,tau蛋白磷酸化导致的神经纤维缠结、免疫激活导致的炎症反应以及褪黑素和GSK-3β等共同途径来相互作用与影响。本文综述了近年来关于昼夜节律紊乱与AD双边关系的研究进展,并总结了目前针对昼夜节律紊乱与AD的治疗方法。 Alzheimer’s disease(AD)is a common neurodegenerative disease.Its pathological features includeβ-amyloid(Aβ)deposition,neuronal death and cognitive decline.In recent years,more and more studies have shown that biological species or circadian rhythm disturbance is closely related to the occurrence and development of AD.25%to 40%of AD patients are accompanied by different degrees of recent rhythm disturbance sleep fragmentation at night,increased daytime napping and other symptoms.The results show that AD and rhythm disturbance can interact and influence through the common pathway,like the generation and clearance of Aβ,neuronal damage and death of neurons,neurofibrillary tangles caused by tau phosphorylation,inflammatory response caused by immune activation,melatonin and GSK-3β.Here,the recent research progress on the bilateral relationship between circadian rhythm disturbance and AD is reviewed,and current treatments for circadian rhythm disturbance and AD are summarized.
作者 李汶阳 夏雨田 麻煜程 江舟 陈军利 Li Wen-yang;Xia Yu-tian;Ma Yu-cheng;Jiang Zhou;Chen Jun-li(West China Institute of Basic Medicine and Forensic Medicine,Sichuan University,Chengdu 610041,China)
出处 《四川生理科学杂志》 2024年第7期1642-1645,共4页
基金 四川省自然科学基金(2022NSFSC0793) 国家卫生健康委员会时间生物学重点实验室开放课题(NHCC-2023-04)。
关键词 阿尔兹海默病 昼夜节律 双边关系 作用途径 治疗方法 Alzheimer’s disease Circadian rhythm Bilateral relationship Pathways of action Therapeutic methods
  • 相关文献

参考文献4

二级参考文献106

  • 1冯晶,李雁鹏,赵忠新.睡眠障碍与疼痛[J].第二军医大学学报,2007,28(5):542-544. 被引量:25
  • 2Abe Y, Hashimoto S, Horie T (1999) Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 39:41-47.
  • 3Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw JJ (2000) Microglia, amyloid and dementia in alzheimer disease. A correlative study. Neurobiol Aging 21:39-47.
  • 4Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, Martins RN (2009) Clearance mechanisms of Alzheimer’s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 14:469-486.
  • 5Bharti AC, Donato N, Aggarwal BB (2003) Curcumin (diferuloylmeth-ane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171:3863-3871.
  • 6Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mul-lan MJ, Sabbagh M, Tariot PN, Group AR (2011) Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimer’s Dement 7:402-411.
  • 7Castello MA, Jeppson JD, Soriano S (2014) Moving beyond anti-amy-loid therapy for the prevention and treatment of Alzheimer’s disease. BMC Neurol 14:169.
  • 8Cole GM, Teter B, Frautschy SA (2007) Neuroprotective effects of curcumin. Adv Exp Med Biol 595:197-212.
  • 9Cox KH, Pipingas A, Scholey AB (2014) Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol pii: 0269881114552744.
  • 10Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K, Soni MG (2011) Safety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studies. Food Chem Toxicol 49:1834-1842.

共引文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部